文献速递泌尿生殖腹部MR

PI-RADS v2.1联合PSAD对有临床意义前列腺癌的诊断价值

Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
PubMed 文献 · Abdom Radiol (NY) · 2022-07-05

回顾性纳入深圳市人民医院2014年11月至2019年11月接受标准前列腺MRI并活检的病例,其中临床有意义前列腺癌(CsPCa)125例、非CsPCa 383例,均按PI-RADS v2.1评分。PI-RADS评分与PSAD为CsPCa独立预测因子,联合模型AUC为0.935;PI-RADS评分≤2分,或PI-RADS评分=3分且PSAD≤0.33 ng/ml/ml时CsPCa检出率低。

要点

  • PI-RADS评分与PSAD值为CsPCa的独立预测因子,联合回归模型AUC为0.935。
  • PI-RADS评分≤2分时CsPCa检出率低。
  • PI-RADS评分=3分且PSAD≤0.33 ng/ml/ml时CsPCa检出率低。

核心结论

  • 联合PI-RADS评分与PSAD值提高了对CsPCa的预测效能;PI-RADS评分≤2分,或PI-RADS评分=3分且PSAD≤0.33 ng/ml/ml的患者可避免不必要的活检。

研究设计与样本

  • 回顾性研究,纳入深圳市人民医院2014年11月至2019年11月行标准前列腺MRI检查并接受前列腺活检的病例,CsPCa 125例、非CsPCa 383例,均按PI-RADS v2.1评分,收集年龄、PSA、游离PSA/总PSA、前列腺体积及PSAD。

诊断标准与关键数值

  • 除年龄外,CsPCa组与非CsPCa组间所有指标差异均有统计学意义;PI-RADS评分与PSAD值诊断价值最高;PI-RADS评分与PSAD值为CsPCa独立预测因子,回归模型AUC为0.935;PI-RADS评分≤2分或PI-RADS评分=3分且PSAD≤0.33 ng/ml/ml时CsPCa检出率低。

临床应用与阅片要点

  • 作者认为,联合PI-RADS评分与PSAD值可提高对CsPCa的预测效能;PI-RADS评分≤2分,或PI-RADS评分=3分且PSAD≤0.33 ng/ml/ml的患者可避免不必要的活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the diagnostic value of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) for clinically significant prostate cancer (CsPCa). We also aimed to combine PI-RADS v2.1 with prostate-specific antigen (PSA) derivatives to improve the predictive value of CsPCa.

METHODS: We retrospectively collected relevant data who underwent standard MRI examinations of the prostate and subjected to a prostate biopsy at Shenzhen People's hospital from November 2014 to November 2019. Included 125 cases of CsPCa and 383 cases of non-CsPCa. All cases were scored using the PI-RADS v2.1. The clinical data collected included age, PSA, free PSA/total PSA, prostate volume and PSA density (PSAD). A univariate analysis was performed to identify statistically significant indicators. Logistic regression was used to analyze the predictive value of the multi-parameter combination on CsPCa.

RESULTS: Except age, the difference in all of indicators between the CsPCa group and non-CsPCa group was statistically significant. The PI-RADS score and PSAD value had the highest diagnostic value. Logistic regression analysis revealed that the PI-RADS score and PSAD value were independent predictors of CsPCa, with a regression model AUC of 0.935. CsPCa detection rates were low when the PI-RADS score ≤ 2 or the PI-RADS score = 3 and the PSAD value ≤ 0.33 ng/ml/ml.

CONCLUSION: Combining the PI-RADS score and PSAD value improved the predictive performance of CsPCa. Patients with a PI-RADS score ≤ 2 or a PI-RADS score = 3 and a PSAD value ≤ 0.33 ng/ml/ml can avoid an unnecessary biopsy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Wei, Xu, Zhong, et al. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer. Abdom Radiol (NY). 2022. PMID: 35788882. doi:10.1007/s00261-022-03592-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。